Democracy 2020 section banner

Actions

UB researchers testing melatonin's effect on mild to moderate COVID-19

Serious coronavirus-linked condition hit 285 US children
Posted at 1:37 PM, Sep 14, 2020
and last updated 2020-09-14 13:37:59-04

BUFFALO, N.Y. (WKBW) — A team of researchers at the University at Buffalo has been approved to test melatonin as a treatment for COVID-19 patients.

The team plans to begin recruiting patients for the trial by October 1st. To be eligible, patients must have tested positive for COVID-19 and have symptoms mild enough that they can be treated at home.

The study will include 30 patients, 20 of whom will receive melatonin and 10 of whom will receive placebo. The study is double-blind, meaning neither the subjects nor the people administering the drug know who is getting melatonin and who is getting placebo. Researchers will use the data from these patients to help determine whether melatonin is safe for COVID-19 patients, and whether it is effective at lessening symptoms.

Previous research shows melatonin can decrease molecules that create inflammation. According to the researchers on this study, high levels of those molecules "are known to contribute to the severity of COVID-19."

Researchers are hoping to find an "inexpensive, widely available treatment" for people with mild to moderate coronavirus.

Anyone interested in participating in the study can sign up here once the trial is open for enrollment.